Skip to main content
. 2015 Feb 7;21(5):1628–1635. doi: 10.3748/wjg.v21.i5.1628

Table 3.

Lymph node micrometastasis positive vs negative groups

Ref. Sample (positive vs negative) Patients who died in 5 yr (positive vs negative) P value
Cai et al[18], 2000 69 (17 vs 52) 3/17 vs 0/52 < 0.01
Fukagawa et al[19], 2001 107 (38 vs 69) 2/38 vs 8/69 0.860
Choi et al[20], 2002 88 (28 vs 60) 2/28 vs 3/60 0.683
Lee et al[21], 2002 153 (75 vs 78) Total: 38/75 vs 19/78; EGC: 2/12 vs 0/34; AGC: 36/63 vs 19/44 < 0.05
Yasuda et al[22], 2002 64 (20 vs 44) 7/20 vs 2/44 < 0.1
Morgagni et al[23], 2003 300 (30 vs 270) 2/30 vs 30/270 0.779
Yonemura et al[24], 2007 308 (37 vs 271) 5/37 vs 16/271 0.014
Kim et al[25], 2008 184 (31 vs 153) 13/31 vs 13/1531 < 0.001
Ishii et al[26], 2008 35 (4 vs 31) - -
Kim et al[27], 2009 90 (9 vs 81) 0/9 vs 0/812 -
Wang et al[28], 2011 191 (54 vs 137) 39/54 vs 18/137 < 0.001
Jeuck et al[29], 2014 95 (16 vs 79) 6/16 vs 21/79 0.026
1

Median survival 17 mo, 95%CI: 7-28 for micrometastasis positive, and median survival not reached, 95%CI: 6-121 mo for micrometastasis negative;

2

Disease-specific survival. EGC: Early gastric cancer; AGC: Advanced gastric cancer.